Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Cancer Discovery
|
April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
Vivek Subbiah, Justin F Gainor, Rami Rahal, et al.
Journal of Medicinal Chemistry
|
August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors
Michele H Potashman, James Bready, Angela Coxon, et al.
Journal of Medicinal Chemistry
|
January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase
Victor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry
|
January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor
Brian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 7, 2012
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
Emily A Peterson, Alessandro A Boezio, Paul S Andrews, et al.
Journal of Medicinal Chemistry
|
February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity
Matthew W Martin, John Newcomb, Joseph J Nunes, et al.
Science Translational Medicine
|
May 29, 2024
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
Alison J Davis, Natasja Brooijmans, Jason D Brubaker, et al.
Journal of Medicinal Chemistry
|
March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation
Erin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry
|
September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity
Erin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Cancer Discovery
|
April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
Vivek Subbiah, Justin F Gainor, Rami Rahal, et al.
Journal of Medicinal Chemistry
|
August 19, 2007
Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors
Michele H Potashman, James Bready, Angela Coxon, et al.
Journal of Medicinal Chemistry
|
January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase
Victor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry
|
January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor
Brian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 7, 2012
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors
Emily A Peterson, Alessandro A Boezio, Paul S Andrews, et al.
Journal of Medicinal Chemistry
|
February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity
Matthew W Martin, John Newcomb, Joseph J Nunes, et al.
Science Translational Medicine
|
May 29, 2024
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
Alison J Davis, Natasja Brooijmans, Jason D Brubaker, et al.
Journal of Medicinal Chemistry
|
March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation
Erin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry
|
September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity
Erin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Page
of 3